An unashamed ramp to newbies!4 Apr 2024 23:12
Thinking about investing ISA money here? Well, here’s a few things to consider.
Covid thrust LFT diagnostics into the limelight, even though anyone who has done a pregnancy test knows it’s existed for decades. Now we’re through the pandemic the sheer number of LFT developers has exploded globally as they search for ways to quickly, accurately and cost effectively achieve diagnosis across a huge range of applications including human, animal, plant pathogen, and environmental testing. These developers are scientists that create biomarkers, the chemistry that attaches to a target to show a result, but they are NOT experts at putting it into a commercial LFT that can be manufactured at scale, nor do they have ready made distribution channels through which to sell.
This is where ABDX comes in, by taking great scientific LFT applications through to commercial success. And this is all against a backdrop of a move towards decentralised, personally managed healthcare which is necessary to release the strain and cost on national health systems.
For the last couple of years the BOD have had a clear plan, and they’ve stuck to and succeeded with it. Build your developer customer base, scale their projects, help them get regulatory approvals, and offer mass manufacturing and established industry and retail distribution channels. All the while it has remained at the forefront of LFT innovation, advancing much more accurate testing methodologies that combine the best of molecular (PCR) with the speed and cost effectiveness of an LFT, as well as advancing far more eco friendly, non plastic, test cassettes.
The business has gone from having just 13 ongoing projects at the beginning of last year to 29 now and of those, 50% are US based, a territory into which the company has also just planted a foothold. And we are now moving into the really interesting phase where the first of our customers developed and approved tests are commercialised and moving into mass manufacturing. More, including those already fast tracked by the NHS for widespread adoption, and targeting significant markets, are coming through the hopper.
It won’t be long at all before we are making millions of tests each month for this diverse customer base across a huge range of applications, and supplying a growing market. And we have few competitors.
And then there’s the management. Well, they own nearly a third of the company and have prudently navigated the company, and its finances, through difficult times to where we sit today. They’ve turned the tanker and now sit ready to put into full throttle.
And if you’re worried about a raise, don’t be, at least not to keep the lights on! The BOD have been crystal clear they don’t like the idea and don’t need to raise in 2024.
So, IMVHO, this is a well run, stable company that has positioned itself superbly to take advantage of an exciting paradigm shift towards rapid testing.
Not a bad place at a
Sign In
Follow the stocks
